Skip to main content
. 2020 Nov 24;27(1):81–89. doi: 10.1111/hae.14205

Figure 3.

Figure 3

Proportion of total time spent with symptoms associated with treated bleeds to the total observation period. QW, every week. Duration of pre‐emicizumab was 0.5 years for all patients. For bleeding that was continuing until the end date of the study, the end date of bleeding was imputed with the end date of the study